Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of SYL040012 in ocular hypertension and open-angle glaucoma
2011-001849-33Phase 2Completed
- Sponsor
- Sylentis
- Start
- Mar 2012
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bamosiran in ocular hypertension and open-angle glaucoma (OAG), sponsored by Sylentis. Primary endpoints: Local ocular tolerability and Change in intraocular pressure. Started Mar 2012; status: completed.
02
Drugs
bamosiran
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2011-001849-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001849-33.